Literature DB >> 22087857

The influence of topical prostaglandin analogues in inflammation after selective laser trabeculoplasty treatment.

Marcelo Ayala1, Enping Chen.   

Abstract

PURPOSE: Reducing intraocular pressure (IOP) seems to be the only treatment that slows progression in glaucoma. The IOP can be decreased by pharmaceutical treatment, laser [selective laser trabeculoplasty (SLT)] treatment, or surgery. Prostaglandin analogues have been postulated to share action mechanisms with SLT and to possibly diminish the effects of SLT treatment. The aim of the current study was to investigate the effects of prostaglandin analogues in inflammation and IOP reduction after SLT treatment.
METHODS: Prospective nonrandomized study. One hundred and eighteen patients were included in the study. INCLUSION CRITERIA: Glaucoma (open-angle or pseudoexfoliation glaucoma) patients who will be treated with SLT. Inflammation was measured with a laser flare meter (Kowa FM-500). Measurements were made before SLT and then 2 h, 1 week, and 1 month after SLT treatment. IOP was also checked at the same time intervals. The SLT treatment was performed over 90°. All patients were divided into two groups: those receiving prostaglandins analogues and those treated with nonprostaglandin analogues.
RESULTS: Inflammation before and after SLT showed no significant difference between the groups at all the time intervals studied (t-test, before: P=0.16; 2 h: P=0.14; 1 week: P=0.12; and 1 month: P=0.36). IOP reduction showed no significant difference between the groups (t-test, P=0.31).
CONCLUSIONS: SLT treatment effects do not seem to be influenced by the use of prostaglandin analogues.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22087857      PMCID: PMC3315161          DOI: 10.1089/jop.2011.0084

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  25 in total

1.  Latanoprost and cystoid macular edema.

Authors:  Anil Negi
Journal:  J Cataract Refract Surg       Date:  2003-06       Impact factor: 3.351

2.  Selective laser trabeculoplasty as primary treatment for open-angle glaucoma: a prospective, nonrandomized pilot study.

Authors:  Shlomo Melamed; Guy J Ben Simon; Hana Levkovitch-Verbin
Journal:  Arch Ophthalmol       Date:  2003-07

3.  PGF(2alpha), a prostanoid released by endothelial cells activated by hypoxia, is a chemoattractant candidate for neutrophil recruitment.

Authors:  T Arnould; R Thibaut-Vercruyssen; N Bouaziz; M Dieu; J Remacle; C Michiels
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

4.  Use of laser flare photometry to assess and monitor inflammation in uveitis.

Authors:  C P Herbort; Y Guex-Crosier; E de Ancos; N Pittet
Journal:  Ophthalmology       Date:  1997-01       Impact factor: 12.079

5.  From the bedside to the bench and back again: predicting and improving the outcomes of SLT glaucoma therapy.

Authors:  Jorge A Alvarado; Rumiko Iguchi; Richard Juster; Julie A Chen; Amde Selassie Shifera
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

Review 6.  Prostaglandins and cystoid macular edema.

Authors:  Kensaku Miyake; Nobuhiro Ibaraki
Journal:  Surv Ophthalmol       Date:  2002-08       Impact factor: 6.048

7.  Crossover comparison of timolol and latanoprost in chronic primary angle-closure glaucoma.

Authors:  Ramanjit Sihota; Rohit Saxena; H C Agarwal; Vikas Gulati
Journal:  Arch Ophthalmol       Date:  2004-02

8.  The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Glaucoma Laser Trial Research Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1995-12       Impact factor: 5.258

9.  In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trabecular cells.

Authors:  Pascale Hamard; Catherine Blondin; Caroline Debbasch; Jean-Michel Warnet; Christophe Baudouin; Françoise Brignole
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-11-07       Impact factor: 3.117

10.  A comparison between 90 degrees and 180 degrees selective laser trabeculoplasty.

Authors:  Enping Chen; Saeed Golchin; Sven Blomdahl
Journal:  J Glaucoma       Date:  2004-02       Impact factor: 2.503

View more
  6 in total

Review 1.  Selective laser trabeculoplasty is safe and effective in patients previously treated with prostaglandin analogs: An evidence-based review.

Authors:  Raul E Ruiz-Lozano; Jimena Alamillo-Velazquez; Gustavo Ortiz-Morales; Lucas A Garza-Garza; Manuel E Quiroga-Garza; Carlos Alvarez-Guzman; Alejandro Rodriguez-Garcia
Journal:  Int Ophthalmol       Date:  2022-08-13       Impact factor: 2.029

2.  Comparison of the effectiveness and safety of travoprost and latanoprost for the management of open-angle glaucoma given as an evening dose.

Authors:  Jing Li; Xiaoyi Wang; Guihua Xu; Ruidong Deng; Laiwei Wu; Liqin Zhang; Zilin Chen
Journal:  Exp Ther Med       Date:  2020-08-28       Impact factor: 2.447

3.  Twenty-four-hour intraocular pressure related changes following adjuvant selective laser trabeculoplasty for normal tension glaucoma.

Authors:  Jacky W Y Lee; Lin Fu; Jonathan C H Chan; Jimmy S M Lai
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

Review 4.  Complications of selective laser trabeculoplasty: a review.

Authors:  Julia Song
Journal:  Clin Ophthalmol       Date:  2016-01-14

5.  Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy.

Authors:  Takako Miki; Tomoko Naito; Miyuki Fujiwara; Ryoichi Araki; Rieko Kiyoi; Yusuke Shiode; Atsushi Fujiwara; Yuki Morizane; Fumio Shiraga
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

Review 6.  A Review of the Clinical Usefulness of Selective Laser Trabeculoplasty in Exfoliative Glaucoma.

Authors:  Andreas Katsanos; Anastasios G Konstas; Dimitrios G Mikropoulos; Luciano Quaranta; Irini C Voudouragkaki; Georgios P Athanasopoulos; Ioannis Asproudis; Miguel A Teus
Journal:  Adv Ther       Date:  2018-04-11       Impact factor: 3.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.